| |
Decentralized clinical trials (DCTs) are redefining clinical research beyond the confines of traditional clinical trial sites. This recent shift presents immense promise for pediatric rare disease research – offering hope to patients and their families as they navigate the uncertainty of their diagnoses. Read our checklist to explore expert insights for the implementation of decentralized clinical trials in pediatric rare diseases. +(002)+120w.png)
|
|
Today’s Big NewsApr 16, 2024 |
| By Annalee Armstrong In a world overrun by innovative biotechs, be a Mammoth Biosciences. Or a Nutcracker Therapeutics. Or Viking Therapeutics or Centessa Pharmaceuticals. |
|
|
|
By James Waldron It’s not unusual to see a CD19-focused cancer company dip its toe into the autoimmune space these days, but Cullinan Oncology is going one stage further with a name change to reflect this new approach. |
By Gabrielle Masson Takeda is offering Kumquat Biosciences the chance to make more than $1.2 billion biobucks in a new exclusive pact that centers around an unnamed immuno-oncology small molecule inhibitor. |
By Kevin Dunleavy For the first time, Johnson & Johnson is reporting sales of its multiple myeloma drug Tecvayli, which is off to a strong launch and contributing to the company's overall strength in treating the disease. |
|
Tuesday, April 23, 2024 | 2:00pm ET | 11:00am PT If you are embarking on the exciting journey of moving labs, this webinar is for you! Join us on April 23rd to learn from real-life stories the critical steps to a successful move and the common budget-draining mistakes to avoid. Register today! 
|
|
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Helen Floersh SelSym's "biomaterials approach" to developing synthetic platelets appears to have paid off so far, with successful results in mice, rats and pigs. The preclinical studies will likely be part of an investigational new drug application with the FDA. |
By Zoey Becker The filling department closure comes as part of a regulatory commitment, a spokesperson said. The site in Kankakee County, Illinois, has been active for 70 years and employs around 1,500 workers. |
By Conor Hale Though the initial green lights cover spine and orthopedic hardware, Orthobond and Onkos Surgical said their respective disinfectants could shield a wide variety of implants. |
By Zoey Becker The company's late-stage pipeline focuses on oncology, cardiorespiratory diseases, mental health and cardiovascular-renal-metabolic conditions. Boehringer looks to kick off ten new phase 2 and 3 trials in the next 12-18 months, it said in its earnings release. |
By Andrea Park The drug’s name—pronounced way-NOO-ah—came about as part of a “lengthy, thoughtful process” between the two companies, according to Rachel Payne, global commercial VP of the ATTR team within AstraZeneca’s cardiovascular, renal and metabolism business. |
Fierce podcasts Don’t miss an episode |
| Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. |
|
|---|
|
|
|
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join usto learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now. 
|
|
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
